Brief: Medivir: FDA Grants MIV-818 ODD For The Treatment Of Hepatocellular Carcinoma

Medivir AB

06/05/2020 07:38

May 6 (Reuters) - Medivir AB  MVIRb.ST :
    * FDA GRANTS MIV-818 ORPHAN DRUG DESIGNATION FOR THE
TREATMENT OF
HEPATOCELLULAR CARCINOMA
    * FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) TO MIV-818 FOR
TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), MOST
COMMON TYPE OF PRIMARY LIVER CANCER.

Source text for Eikon:  ID:nWkr9f8bj 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))